SAN DIEGO, Oct. 27 /PRNewswire/ -- Amira Pharmaceuticals, Inc., a small
molecule pharmaceutical company focused on the discovery and early development
of new drugs to treat inflammatory disease, announced today that Robert
Baltera, Chief Executive Officer, will present a company overview at the 8th
Annual BIO Investor Forum. The presentation is scheduled for 2:30 p.m. PDT on
Thursday, October 29, at the Palace Hotel in San Francisco, Calif. The BIO
Investor Form gives investors the opportunity to hear from and meet with
executives from top life sciences growth companies.
About Amira
Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a
small molecule pharmaceutical company focused on the discovery and early
development of new drugs to treat inflammatory disease. Our discovery team is
building on unparalleled insights into bioactive lipid pathways and complex
signaling processes controlling many conditions including asthma, chronic
obstructive pulmonary disease, cardiovascular and fibrotic diseases. Amira
has a partnership with GlaxoSmithKline for the development of FLAP
(5-lipoxygenase activating protein) inhibitors in respiratory and
cardiovascular disease.
Amira combines the rigor of a big pharmaceutical company with the ingenuity
and energy of a small company, creating an environment for efficient
development of novel compounds and effective pre-clinical and clinical program
decisions. Its scientific founders have successfully worked together for more
than a decade and were pivotal in the discovery of a number of inflammatory
drugs, including Singulair®. The drug hunters at Amira are now actively
leveraging their history of success to create high-value compounds for the
future. For more information, visit www.amirapharm.com.
SOURCE Amira Pharmaceuticals, Inc.
Ian Stone of Russo Partners, +1-619-528-2220, ian.stone@russopartnersllc.com,
for Amira Pharmaceuticals, Inc.
